Atea Pharmaceuticals Inc Stock News

Atea Pharmaceuticals (AVIR) offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines advantages of current first-line HCV therapies — single pill, no drug-drug or food interactions, short treatment, and high barrier to resistance. Phase 3 readouts for BEM/RZR are expected in 2026, with positive data likely to drive a strategic transact...

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C- BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivir...

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team,...

Atea Pharmaceuticals, Inc. ( AVIR ) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Company Participants Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Jonae Barnes - Senior Vice President of Inv...

Atea Pharmaceuticals, Inc. ( AVIR ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - CFO, ...

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting ® , the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV Company A...

Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12, 2025, at 4:30 p.m. ET to report financial results...